Shenzhen Hepalink Pharmaceutical Group Co Ltd’s stock price surges 8% after successful completion of Phase I clinical trial for innovative drug candidate H1710.

Shenzhen Hepalink Pharmaceutical Group Co Ltd has made significant strides in the pharmaceutical industry, achieving a clinical trial milestone, expanding international production capacity, and solidifying its market position as the largest global p…

Shenzhen Hepalink Pharmaceutical Group Co Ltd reported a profit of 0.11 HKD per share for Q1 2025, marking a positive development for the company after facing financial challenges.